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Abstract
Macular degeneration is a common cause of blindness in the elderly. To identify rare coding
variants associated with a large increase in risk of age-related macular degeneration (AMD), we
sequenced 2,335 cases and 789 controls in 10 candidate loci (57 genes). To increase power, we
augmented our control set with ancestry-matched exome sequenced controls. An analysis of
coding variation in 2,268 AMD cases and 2,268 ancestry matched controls revealed two large-
effect rare variants; previously described R1210C in the CFH gene (fcase = 0.51%, fcontrol =
0.02%, OR = 23.11), and newly identified K155Q in the C3 gene (fcase = 1.06%, fcontrol = 0.39%,
OR = 2.68). The variants suggest decreased inhibition of C3 by Factor H, resulting in increased
activation of the alternative complement pathway, as a key component of disease biology.
Genetic and environmental factors contribute to age-related macular degeneration
(AMD)1,2, a major cause of vision loss in elderly individuals3. Pioneering discovery of
association of AMD with complement factor H (CFH4–6) was quickly followed by the
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tidentification of additional susceptibility loci that now include ARMS2/HTRA17,8 and
complement genes C3, C2/CFB and CFI9–12. Genome-wide association studies (GWAS) of
AMD cases and controls have now revealed common susceptibility variants at ~20 different
loci13,14 and begun to uncover specific cellular pathways involved in AMD biology.
While common variants tag the associated genomic region, rare coding variants can provide
more specific clues about the underlying disease mechanism15. For example, rare variant
R1210C in the CFH gene was recently associated with a large increase in AMD risk using
targeted sequencing of rare CFH risk haplotypes16. The resulting altered protein has
decreased binding to C3b, C3d, heparin and endothelial cells17–19. A reduction in CFH’s
ability to inactivate C3, leading to increased cell killing activity by the complement
pathway, could contribute to AMD – a much more specific and testable hypothesis about
disease mechanism than provided by common CFH variants whose mechanistic
consequences are unclear.
To systematically identify rare, large-effect variants, we carried out targeted sequencing of
eight AMD risk loci identified in GWAS20 (near CFH, ARMS2, C3, C2/CFB, CFI, CETP,
LIPC and TIMP3/SYN3) and two candidate regions (LPL and ABCA1) (Supplementary
Table 1). We re-sequenced these regions in 3,124 individuals (2,335 cases and 789 controls)
recruited in ophthalmology clinics at the University of Michigan and at the University of
Pennsylvania and among Age-Related Eye Disease Study (AREDS)
participants20,21_ENREF_17. Genomic targets were enriched using a set of 150-bp probes
designed by Agilent Technologies, and sequence data was generated on Illumina Genome
Analyzer and HiSeq instruments. The ten loci comprised 115,596 nucleotides of protein
coding sequence and totaled 2,757,914 nucleotides overall. We designed probes to capture
111,592 protein coding nucleotides (96.5% of coding sequence) and 966,607 nucleotides
overall (35.1 % of the locus sequence), generating an average of 123,221,974 mapped bases
of on-target sequence per individual (127.5× average depth counting bases with quality >20
in reads with mapping quality >30, after duplicate read removal); 98.49% of sites with
designed probes were covered at >10× depth. We applied variant calling tools and quality
control filters similar to those used to analyze NHLBI Exome Sequencing Project data22
(Supplementary Table 2). We identified an average of 1,714 non-reference sites in each
sequenced individual. In total, this resulted in 31,527 single nucleotide variants of which
18,956 were not in dbSNP 135. Discovered sites included 834 synonymous variants, 1,379
nonsynonymous variants and 43 nonsense variants, most of which were extremely rare (see
Supplementary Table 3). Among 13 samples sequenced in duplicate, genotype concordance
was 99.82% (when depth >10×). Among 908 samples previously examined with GWAS
arrays20, sequence-based genotypes were 98.99% concordant with array-based calls (again,
when depth >10×).
In an initial comparison of AMD cases and controls (see Supplementary Table 4), no rare
coding variants with frequency <1% reached experiment wide significance (p < 0.05 /
31,527 = 1.6×10−6, including all discovered variants, or p < 0.05 / 1,422 = 3.5×10−5
considering only protein altering variants), although several showed encouraging patterns.
For example, rare variant R1210C in the CFH gene was observed in 23 of the 2,335
sequenced cases, but in none of the 789 sequenced controls (exact test p=0.0025). Common
variants in several loci exhibited strong evidence of association, including in CFH (peak
variant rs9427642 with case frequency fcase = 12%, control frequency fcontrol = 27%, P-
value = 2.52×10−48), ARMS2 (rs10490924, fcase = 33%, fcontrol = 18%, P-value =
5.48×10−27), C3 (rs2230199, fcase = 25%, fcontrol = 17%, P-value = 3.94×10−9) and C2/CFB
(rs556679, fcase = 7%, fcontrol = 12%, P-value = 1.32×10−10).
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tA key requirement for establishing significance of rare disease associated variants is the
availability of sufficient numbers of control samples. To increase power, we sought to
identify additional controls and focused on samples from the NHLBI Exome Sequencing
Project (ESP)23, which sequenced 15,336 genes across 6,515 individuals. Sequence data for
our samples and the NHLBI Exome Sequencing Project samples were analyzed with the
same analysis pipeline, which minimized potential differences due to heterogeneity in
analysis tools and parameters. To further avoid sequencing and variant calling artifacts, we
restricted our analysis to sites within regions targeted in both sequencing experiments,
genotyped and covered with >10 reads in >90% of the samples examined in each project,
and >5-bp away from insertion/deletion polymorphisms catalogued by the 1000 Genomes
Project24. Since careful matching of genetic ancestry is critical for rare variant association
studies24,25, we selected an ancestry-matched subset of our samples and of samples from the
NHLBI Exome Sequencing Project. We used principal component analysis to construct a
genetic ancestry map of the world with samples from the Human Genome Diversity Project,
each genotyped at 632,958 SNPs26. If GWAS array genotypes were available for our
samples and for the NHLBI Exome Sequencing Project samples, it would be straightforward
to place them directly in this genetic ancestry map. Using targeted sequence data, however,
the analysis is more challenging: targeted regions include too few variants to accurately
represent global ancestry and off-target regions are covered too poorly, precluding
estimation of the accurate genotypes needed for standard principal component analysis.
Thus, we relied on the new LASER algorithm (Wang and Abecasis, personal
communication) to place each sequenced sample in a pre-defined genetic ancestry map of
the world. The method can accurately place individuals on this worldwide ancestry map
with <0.05× average coverage of the genome and is thus ideal for targeted sequence data,
such as ours and the NHLBI Exome Sequence data, which have average off-target coverage
of ~0.23× and ~0.90×, respectively (see Supplementary Figures 1A, 1B, 1E and 1F, which
show that PCA coordinates inferred using 0.10× genome coverage or using GWAS array
genotypes are highly similar). We focused on samples where PCA coordinates could be
estimated confidently (Procrustes similarity larger than 0.95; see Online Methods) and used
a greedy algorithm to match cases and controls based on estimated genetic ancestry. As
shown in the Online Methods, alternative matching algorithms do not alter our conclusions.
After matching, we focused on a set of 2,268 AMD cases and 2,268 controls, ancestry-
matched one-to-one (Supplementary Figure 1C and 1G). Since AMD phenotype information
was not available for most controls, we expect that a small proportion may eventually
develop disease; however, this should not impact power substantially27. After matching
case-control samples, we excluded 1 variant with Hardy-Weinberg Equilibrium test p-value
<10−6 and focused our analysis on 430 protein changing variants in regions that were
targeted and deeply sequenced in both experiments as well as far away from insertion
deletion polymorphisms.
In this expanded analysis (see Table 1), common variant signals at all loci increased in
significance (in comparison to Supplementary Table 4). In addition, two rare coding variants
exhibited association with p < 0.01. The first was R1210C in the CFH gene (observed in one
control and 23 cases, OR = 23.11, pexact = 2.9×10−6), providing strong support for the
original report16. The second variant was K155Q in the C3 gene (18 controls, 48 cases, OR
= 2.68, pexact = 2.7×10−4; Supplementary Figure 1D and 1H for carrier ancestry
distribution). When controlling for a previously described common variant signal nearby,
rs2230199 (fcontrol = 20.63%, fcase = 25.26%, marginal pexact = 1.8×10−7, OR = 1.31), the
evidence for association with K155Q increased slightly (conditional OR = 2.91, pexact =
2.8×10−5). Inspection of the raw read data shows the variant is well supported and is
unlikely to be a sequencing or alignment artifact, a result further confirmed by Sanger
sequencing (see Supplementary Figures 2, 3 and 4). Finally, in an examination of our
sequenced samples and available whole genome sequences (Online Methods), we observed
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tno additional variants in strong linkage disequilibrium with K155Q that might account for
the association signal. Analysis with burden tests, which jointly evaluate evidence for
association with rare variants at each gene, identified no significant association signals
(Supplementary Figure 5)28–30.
To confirm the K155Q signal, we genotyped additional samples totaling 4,526 cases and
3,787 controls and, again, observed strong association (fcontrol = 0.5%, fcase = 1.3%,
pfollow-up = 7.7×10−7, pcombined = 1.1×10−9, Table 2). In addition, we genotyped 471
families with multiple AMD cases to identify 18 nuclear families where K155Q segregates.
These families included 49 affected individuals, where at least one individual carries K155Q
and, adjusting for ascertainment, we estimate that 75% of first degree relatives of a K155Q
carrier who also have AMD will carry the variant, consistent with an OR of ~3
(Supplementary Table 5 and Online Material). Further strong evidence for association of
this variant with macular degeneration is provided in independent work by deCODE
Genetics31, examining 1,143 Icelandic macular degeneration cases and 51,435 Icelandic
controls (control frequency 0.55%, OR = 3.45, pdeCODE = 1.1×10−7, pcombined = 1.6×10−15).
In 1,606 directly genotyped cases of macular degeneration from the Age Related Disease
Study II32 the variant has frequency 1.77%, similar to our sequenced AMD cases (frequency
1.10%) and our follow-up AMD cases (1.30%) and is notably higher than in our sequenced
controls (0.30%), our genotyped controls (0.50%), in NHLBI Exome Sequencing Project
participants with primarily European Ancestry (0.40%) and in deCODE controls (0.55%).
We found no evidence of the K155Q variant in a small sample of patients with atypical
haemolytic-uremic syndrome (aHUS, n=53), a rare disorder whose genetic risk factors
partially overlap with macular degeneration.
We next investigated the potential functional consequences of the K155Q variant in silico.
Based on protein crystallography, the model in Figure 1 shows that CFH variant R1210C
(OR=23.11), C3 variant K155Q (OR=2.91) and C3 variant R102G (OR=1.31) all map near
the surface where CFH and C3b interact and suggests they might affect binding of
complement factor H to C3b. Factor H inhibits C3b and limits immune responses mediated
by the alternative complement pathway. We hypothesize that K155Q and R102G affect
binding of the first macro-globular domain of C3 to CFH and thus interferes with
inactivation of the alternative complement pathway_ENREF_31, a hypothesis that must be
confirmed experimentally33. Interestingly, the three variants (R102G and K155Q in C3 and
R1210C in CFH) all are associated with replacement of a positively charged residue.
In summary, our work and the companion paper identify K155Q as a rare C3 variant
associated with a ~2.91-fold increased risk of macular degeneration. Together with rare CFH
variant R1210C and previously described common C3 variant R102G, K155Q may reduce
binding of CFH to C3b, inhibiting the ability of Factor H to inactivate the alternative
complement pathway. Clarifying the mechanistic impact of K155Q is likely to be
challenging, as illustrated by contradictory results of previous functional follow-up of AMD
loci34–36, but functional studies of complement activity suggest potential next steps33,37.
Our work relied on targeted sequencing of GWAS loci, genetic ancestry matching of our
sequenced samples to additional sequenced controls analyzed with the same variant calling
and filtering tools, focused analysis of regions deeply sequenced in both our project and
previously sequenced controls, and avoidance of common calling artifacts near insertion/
deletion polymorphisms. The use of publicly available samples to augment control sets may
be useful to many targeted sequencing studies, but the strictness of matching and variant
filtering required for preventing false-positive findings due to population stratification and/
or sequence analysis artifacts are areas deserving of further study. As the number of
sequenced human genomes and exomes grows, we expect that the utility of the approach
will grow – making it possible to match multiple controls to each case and to focus on
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tprogressively finer ancestry matches. Our results also emphasize the challenges and the
large sample sizes will be required for rare variant studies of complex human traits, as well
as the promise of these studies to highlight disease biology, as illustrated by the interaction
between Factor H and C3b that is suggested as a key factor in AMD biology here.
Online Methods
Study samples
Macular degeneration cases and controls were recruited at Ophthalmology clinics at the
University of Michigan and the University of Pennsylvania and through the Age Related
Eye Diseases Study, as previously described. For replication, we contacted members of the
International AMD Genetics Consortium; their samples are described in Fritsche et al13. All
participants provided informed consent allowing for collection of genetic data and all data
contributors obtained approval from their local Institutional Review Boards before
generating genetic data. Our discovery sample, with ~2350 sequenced cases and ~750
sequenced controls, provides 90% power to discover variants with a frequency of 0.1% and
an associated relative risk of 19.2 or greater (similar to CFH R1210C) at significance level
alpha = 0.00005, which corresponds to an adjustment for analysis of 1,000 independent
coding variants.
Sequence production and quality control
Illumina multiplexed libraries were constructed according to the manufacturer’s protocol
(Illumina Inc, San Diego, CA) with modifications: 1) DNA was fragmented using a Covaris
E220 DNA Sonicator (Covaris, Inc. Woburn, MA) to range in size between 100 and 400bp.
2) Illumina adapter-ligated library fragments were amplified in four 50μ L PCR reactions for
eighteen cycles. 3) Solid Phase Reversible Immobilization (SPRI) bead cleanup was used for
enzymatic purification and final library size selection targeting 300–500bp fragments.
Samples were pooled in groups of 4–24 before hybridization. A custom targeted probe set of
150bp probes was designed (Agilent Technologies, Santa Clara, CA) and captured 0.97 Mb
of sequence. The concentration of each captured library pool was determined through qPCR
(Kapa Biosystems, Inc, Woburn, MA) to produce cluster counts appropriate for the Illumina
GAIIx and HiSeq 2000 platforms. We generated approximately 1.7Gb of sequence per
sample, covering 80% of the targeted space at depth >20×. Reads were aligned to the
NCBI37/hg19 reference sequence using BWA38. Where pre-existing genotype information
was available, sample identity was confirmed by comparing sequence data with pre-existing
array data.
Quality control and variant calling
Quality control steps for all BAM files included: removal of duplicated reads; recalibration
of base qualities39; generation of diagnostic graphs and evaluation of sequencing quality40;
checks for DNA contamination41. After removing samples with high contamination,
unexpected relatedness or with high discordance rate, we retained 2,335 cases and 789
controls for an initial round of analysis. We calculated the sequencing depth using reads
with mapping quality >30 and bases with quality >20. Across the 966,607 base pair target
region, we retained an average 123,221,974 bases per individual (127.5× average coverage).
Within targeted regions, 98.49% of the protein coding exons had coverage >10×.
We performed variant calling step using UMAKE23. Genotype calling and polymorphism
discovery were attempted across the original target +/− 50 basepairs. To remove low quality
variants, we excluded: 1) sites with average depth <0.5 or >500; 2) sites with evidence of
strand bias or cycle bias; 3) sites within 5 basepairs of a 1000 Genomes Project indel; 4)
sites with excess heterozygosity. These filters excluded 15,219 low quality variants. The
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ttransition-transversion ratio (Ts/Tv) for the remaining 31,527 site was 2.10. Concordance
rates between sequence-based genotypes in 13 duplicates were 99.82% when depth >10×.
Concordance with array-based genotypes20 was 98.99% when depth >10×.
59.8% of discovered variants are novel (versus dbSNP 135 and the 1000 Genomes Project).
On average, each sample carried 40 synonymous variants, 34 nonsynonymous variants and 1
nonsense variant.
Initial analyses
We first performed single variant association tests using Fisher’s exact test. This analysis
confirmed strong association for common variants near CFH, C2, ARMS2 and C3 genes. An
initial examination of rare variants suggested some signals were shadows of common
variants with larger effects, so we focused on those where association remained significant
after accounting for nearby common variants. Conditional signals were evaluated by exact
logistic regression42,43. Three coding variants had conditional exact P-value less than 0.01
(all also had marginal p-values < 0.01).
Augmenting our sample
We sought ancestry matched controls among samples sequenced in the ESP project. First,
we used genome-wide reads to infer sample ancestries on a worldwide population map.
Briefly, we first generated a genetic ancestry PCA space using genotyped reference samples
(such as those from the Human Genome Diversity Panel). Then, we generated a series of
sample specific genetic ancestry PCA that are calibrated to the exact sequencing depth and
coverage pattern of each sample and include the reference samples together with a single
sequenced sample. Finally, we transformed sample specific PCA coordinates to the original
map using Procrustes analysis. This procedure generates a metric (the Procrustes similarity)
that summarizes similarity of reference sample placements using array genotypes to
placements using sequence data and we only considered samples where this metric was
>0.95 as candidates for matching. Second, we used a procedure inspired on propensity score
matching to pair cases and controls44. Briefly, this procedure uses logistic regression to
predict the probability that an individual is a case using the four principal components of
ancestry as predictors and disease status as the outcome. This estimated probability of being
a case for each sample is a propensity score and can be used to match cases and controls. For
matching, we used a greedy algorithm to match cases and controls; allowing matches when
the respective propensity scores differed by <.0001. An alternative matching algorithm that
matched cases and controls mapping close together in principal component space according
to the Euclidean distance between them gave similar results (association at K155Q had
OR=2.68, exact p-value 4.5×10−5 using Fisher’s exact test).
To avoid variant calling artifacts, we applied very stringent filters to both the AMD study
and ESP study call sets. For both studies, we examined only sites with call rates >90%,
Phred-scaled variant quality scores >30, passing all study specific quality control filters,
with depth >10× for >90% of the samples in the AMD or ESP callsets, and >5-bp from a
1000 Genomes Project indel. Primers used to confirm the presence of K155Q by Sanger
Sequencing are given in Supplementary Table 6.
Analyses using the combined AMD and ESP data set
Similar to our initial analysis, we first applied Fisher’s exact test for association to all
variants. Next, we examined variants with frequency <1% for which signal remained
significant after adjusting for common variants. This analysis highlighted R1210C in CFH
and K155Q in C3 (Figure 1).
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To search for variants that might explain the signal at K155Q, we evaluated linkage
disequilibrium between K155Q and all variants within 1 Mb both within the samples
sequenced for this experiment and also in preliminary whole genome sequence data for 600
individuals (300 macular degeneration cases, 300 controls; Swaroop, Stambolian and
Abecasis, personal communication). This analysis did not find variants in strong linkage
disequilibrium in the nearby region. The variant is only present in one 1000 Genomes
Project sample, which does not allow for reliable estimates of linkage disequilibrium.
Segregation analysis
In a segregation analysis, one identifies probands who carry K155Q and then evaluates the
probability that they transmit the variant to affected relatives (under the null, we would
expect to find the variant in 50% of first degree relatives of a carrier). We genotyped 471
pedigrees with multiple affected individuals. In each pedigree where K155Q was found in
>1 affected individual, we selected the nuclear family with the largest number of affected
individuals. We recorded the number of affected individuals (N) and the number of K155Q
carriers (C). Then, to average over possible choices of proband, we assigned each family a
weight of C/N (this is the probability that a randomly selected proband in the family carries
K155Q) and then scored the number of affected first degree relatives (N-1) and of carriers
among those (C-1). The estimated fraction of carriers among affected first degree relatives
of a proband is then calculated by summing C/N * (C-1) and C/N * (N-1) over families and
taking the ratio of the two quantities.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1.
C3 variants R102G and K155Q and CFH variant R1210C are in the interaction domains of
the first alpha-macro-globular domain of C3b and CFH, respectively. The fragment of the
crystal structure of the four Sushi domains (purple in figure, one not shown for clarity) of
CFH in a complex with complement fragment C3b (PDB file: 2wii) was used to explore the
effect of disease associated nonsynonymous changes. The CFH residues 987–1230 were
used to generate the structure using the first four Sushi domains from 2wii as a structural
template (shown in pink, with cysteine residue side chains in yellow). The C-terminal Sushi
domains were docked to the binding site in C3b. The first two alpha-macro-globulin
domains of C3b, MG-1 and MG-2, are shown in green and cyan, respectively. The location
of mutations R102G, K155Q, and R1210C are marked in red.
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